Event recap:
Insights from ISPOR Europe 2024
Our thought leadership in action
Explore some of our expert contributions, posters and related content that showcased our commitment to help commercialization challenges for our partners and patients they serve.
Accelerate patient access to innovation across Europe
500+
HTA submissions delivered across Europe in last 5 years
1,300+
global locations
25+
years of industry experience and knowledge
Poster presentation
The research our experts presented during ISPOR Europe 2024 covered everything from the most critical challenges facing healthcare and the upcoming EU Joint Clinical Assessment (JCA) to showcasing groundbreaking solutions and the latest advancements in HEOR. Download the posters here to learn more about our findings.
- Comparative analysis of key market access dossiers: How global, European, German, and United States dossier formats compare in terms of structure, timing, and application
- Literature search approaches in an era of increasing publication volume
- Authorization and financing situation in Spain of the new medicines and indications authorized by the European Commission in the period 2021-2023
- Analysis of IPT developed for the new medicines and indications authorized by the European Commission during the 2021-2023 period
- Is an AMNOG benefit reassessment after time limitation really a risk to drug prices?
- Indirect comparisons in German AMNOG assessments: Keep the faith
- Do orphan drugs lack evidence in health technology assessments compared to non-orphan drugs?
- The last of fungus? Recent development of fungal infections in German hospital settings
- Regional differences in morbidity across Germany: A cross-state comparison using hospital data
- Methodological quality checklists in systematic literature reviews of health economic evaluations, 2022-2024
- Economic impact model to estimate the value of blood-based biomarkers in the risk assessment of pulmonary nodules from a health system perspective
- Early Alzheimer's disease in Germany: Patient pathways preceding pharmaceutical treatment
- Real-world prescribing patterns of glucagon-like peptide-1 receptor agonists in Germany
- Post-authorization safety study of the SQ Tree sublingual immunotherapy tablet in real-life practice across Europe
- Challenges of missing specific disease codes: Estimating incidence and prevalence of immunoglobulin A nephropathy (IgAN) using health insurance claims data
- Impact of EMA's conditional marketing authorizations on the benefit assessment validity period in Germany: Insights from 2017-2023
- Understanding joint clinical assessment scoping requirements in oncology: Results of a rapid PICO prediction exercise via an in-house expert network
- Expediting reimbursement and access for novel drug indications in Europe: A case study on glucagon-like peptide 1 agonists
Catch up on our latest insights
Webinar
Achieving broad access fast! What will it take for innovative medicines to succeed?
December 3, 2024 | 4:30PM CET; 3:30PM GMT; 10:30AM EST
Anticipating the launch of the joint clinical assessment (JCA) in January 2025, the healthcare industry in Europe is preparing for a transformative shift in how innovations are evaluated and approved. Join us as we unravel the essential healthcare system requirements and policies crucial for accelerating patient access to groundbreaking medicines.
Anticipating the launch of the joint clinical assessment (JCA) in January 2025, the healthcare industry in Europe is preparing for a transformative shift in how innovations are evaluated and approved. Join us as we unravel the essential healthcare system requirements and policies crucial for accelerating patient access to groundbreaking medicines.
Resource Center
European Health Technology Assessment (HTA)
As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the imminent implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. With only weeks remaining until its full integration, we invite you to explore a wealth of insights that delve deep into the intricacies of this transformative initiative.
Winter 2024
Catch up on the latest edition of HTA Quarterly
In this edition, we look ahead to the introduction of the European Union (EU) Joint Clinical Assessment (JCA), with a focus on predicting likely PICOs (population, intervention, comparator, outcomes) mandated in the submission template. Two related articles review completed German AMNOG assessments in detail to evaluate how the stringent G-BA requirements translate into practice, considering how evidence requirements vary between orphan and non-orphan drugs, and acceptance – or not – of indirect comparisons when head-to-head evidence is not available.
